Thyrocare Technologies has initiated a postal ballot to secure shareholder approval for the sale of its 100% stake in subsidiary Nueclear Healthcare to Trovera Healthcare for Rs 141.40 crore. Simultaneously, the company plans to acquire two key laboratory properties from Nueclear for Rs 20.59 crore to ensure operational continuity. This strategic shift aims to exit the radiology business and sharpen the company's focus on its core diagnostics operations.
Thyrocare to Divest Nueclear Healthcare and Streamline Operations
Thyrocare Technologies is divesting its 100% stake in Nueclear Healthcare Limited (NHL) for Rs 141.40 crore and acquiring key laboratory assets for Rs 20.59 crore.
Reader Takeaway: The move sheds non-core radiology assets to prioritize core diagnostic business, boosting balance sheet focus.
What just happened
Thyrocare Technologies has launched a postal ballot process seeking shareholder approval for two major strategic moves. First, it intends to purchase land and building assets currently owned by its subsidiary, Nueclear Healthcare, located in Gurugram and Hyderabad, for Rs 20.59 crore. Second, the company plans to sell its entire 100% equity stake in Nueclear Healthcare to Trovera Healthcare Private Limited for Rs 141.40 crore, comprising Rs 59.50 crore in Compulsorily Convertible Preference Shares (CCPS) and approximately Rs 81.90 crore in cash.
Why this matters
The transaction signifies Thyrocare's intent to exit the radiology space entirely. By acquiring the laboratory properties before the divestment, the company secures its physical operations, avoiding future rental costs and potential disruption. The cash inflow from the divestment will be directed toward general corporate purposes, potentially strengthening the company’s liquidity as it narrows its focus toward the high-margin core diagnostics segment.
The backstory
Thyrocare has been evaluating its business portfolio to improve operational efficiency. Currently, the company operates diagnostic labs at the sites owned by its subsidiary, paying rent to NHL. The proposed divestment is designed to simplify the corporate structure and transfer the specialized radiology business to an entity better positioned to manage it.
Risks to watch
As this involves the divestment of a material subsidiary, the resolution requires mandatory approval from a majority of public shareholders under SEBI’s Regulation 37A. Investors should track the voting outcome, as any failure to secure the necessary majority would stall the strategic realignment.
What to track next
The remote e-voting process commences on September 30, 2026, and concludes on October 29, 2026. The results are expected to be declared by November 02, 2026.